80.6%
mCRPCsolid tumorshematological malignanciesmetastatic castration-resistant prostate cancer (mCRPC)prostate tumorsAB-3028TCGAThe Cancer Genome AtlasGTExChimeric Antigen Receptor T (CAR T) cell therapies
…ns These collective data support the development of AB-3028 for mCRPC.…